Chemotherapy-induced nausea and vomiting in acute leukemia and stem cell transplant patients: Results of a multicenter, observational study

Haematologica

Volumn 91, Issue 1, 2006, Pages 84-91

  López Jiménez, Javier ^a,i,j   Martín Ballesteros, Eva ^b   Sureda, Anna ^c   Uralburu, Carla ^d   Lorenzo, Ignacio ^e   Del Campo, Raquel ^f   Fernández, Cristina ^g   Calbacho, María ^a   García Belmonte, Daniel ^a   Fernández, Gonzalo ^h  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

^b Hospital Princesa   (Spain)

^c Hospital Sant Pau I Santa Creu   (Spain)

^d Servicio de Enfermedades Autoinmunes H Clinic   (Spain)

^e HOSPITAL UNIVERSITARIO LA FE   (Spain)

^f Son Dureta   (Spain)

^g U Epidemiología Clínica H S Carlos   (Spain)

^h Dpto Médico MSD   (Spain)

ⁱ UNIVERSITY OF ALCALÁ   (Spain)

^j H Ramón y Cajal ^*  (Spain)

more..

Author keywords

Chemotherapy; Emesis; Leukemia; Nausea; Transplant; Vomiting

Indexed keywords

ANTHRACYCLINE; CARMUSTINE; CYCLOPHOSPHAMIDE; CYTARABINE; ETOPOSIDE; MELPHALAN; SEROTONIN ANTAGONIST;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ARTICLE; CANCER CHEMOTHERAPY; CAREGIVER; CHEMOTHERAPY INDUCED EMESIS; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; FOLLOW UP; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; NAUSEA AND VOMITING; PROPHYLAXIS; QUALITY OF LIFE; QUESTIONNAIRE; RISK FACTOR; STEM CELL TRANSPLANTATION; VOMITING; WHOLE BODY RADIATION;

ACUTE DISEASE; ANTINEOPLASTIC AGENTS; FEMALE; FOLLOW-UP STUDIES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA; MALE; MIDDLE AGED; NAUSEA; PROSPECTIVE STUDIES; SEROTONIN ANTAGONISTS; TRANSPLANTATION CONDITIONING; VOMITING;

EID: 32544449498     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Ono K, Uchida I, Uno N, Ohno E, Hirota K, Nakayama T, et al. Efficacy of combination with granisetron and methylprednisolone for nausea, vomiting and appetite loss in remission induction chemotherapy of acute myeloid leukemia - a randomized comparative trial between granisetron alone and granisetron plus methylprednisolone. Can To Kagaku Ryoho 1999; 26:821-8.
2. Abbott B, Ippoliti C, Bruton J, J Neumann, R Whaley, R Champlin. Granisetron for antiemetic control in bone marrow transplant patients receiving highly emetogenic chemotherapy with total body irradiation. Proc Am Soc Clin Oncol 1997;16:A150.
3. Osowski CL, Dix SP, Lynn M, Davidson T, Cohen L, Miyahara T, et al. An open-label dose comparison study of ondansetron for the prevention of emesis associated with chemotherapy prior to bone marrow transplantation. Support Care Cancer 1998;:511-7.
4. National Comprehensive Cancer Network. Antiemesis. Clinical Practice Guidelines in Oncology, 2005. www. nccn.org
5. Morrow GR, Roscoe JA, Kirshner JJ, Hynes HE, Rosenbluth RJ. Anticipatory nausea and vomiting in the era of 5-HT3 antiemetics. Sup Car Cancer 1998; 6:244-7.
6. The Italian group for antiemetic research. Transferability to clinical practice of the results of controlled clinical trials: the case of antiemetic prophylactic treatment for cancer chemotherapy-induced nausea and vomiting. Ann Oncol 1998;9:759-65.
7. Hesketh PJ, Kris MG, Grumberg SM, Beck T, Hainsworth JD, Harker G, et al. Proposal for classifiying the acute emetogenicity of cancer chemotherapy. J Clin Oncol 1997;15:103-9.
8. Hesketh PJ. Defining the emetogenicity of cancer chemotherapy regimens: relevance to clinical practice. The Oncologist 1999;4:191-6.
9. Gralla RJ, Navari RM, Hesketh PJ, Popovic W, Strupp J, Noy J, et al. Single dose oral granisetron has equivalent antiemetic efficacy to intravenous ondansetron for highly emetogenic cisplatin-based chemotherapy. J Clin Oncol 1998;16:1568-73.
10. Martin AR, Pearson JD, Cai B, Elmer M, Horgan K, Lindley C. Assessing the impact of chemotherapy-induced nausea and vomiting on patients' daily lives: a modified version of the Functional Living Index-Emesis (FEIE) with 5-day recall. Support Care Cancer 2003;11:522-7.
11. Olver I, Paska W, Depierre A, Seitz JF, Stewart DJ, Goedhals E, et al. A multicentre, double-blind study comparing placebo, ondansetron and ondansetron plus dexamethasone for the control of cisplatin-induced delayed emesis. Ondansetron Delayed Emesis Study Group. Ann Oncol 1996;7:945-52.
12. Osoba D, Zee B, Warr D, Latreille J, Kaizer L, Pater J. Effect of postchemotherapy nausea and vomiting on health-related quality of life. The Quality of Life and Symptom Control Committees of the National Cancer Institute of Canada Clinical Trials Group. Support Care Cancer 1997;5:307-13.
13. Komada Y, Matsuyama T, Takao A, Hongo T, Nishimura Y, Horibe K, et al. A randomised dose-comparison trial of granisetron in preventing emesis in children with leukaemia receiving emetogenic chemotherapy. Eur J Cancer 1999;35:1095-101.
14. Matsuoka S, Okamoto S, Watanabe R, Mori T, Nagayama H, Hamano Y, et al. Granisetron plus dexamethasone versus granisetron alone in the prevention of vomiting induced by conditioning for stem cell transplantation: a prospective randomized study. Int J Hematol 2003;77:86-90.
15. Barbounis V, Koumakis G, Hatzichristour H, Vassilomanolakis M, Tsoussos S, Efremidis A. The antiemetic efficacy of tropiseton plus dexamethasone in patients treated with high-dose chemotherapy and stem cell transplantation. Support Care Cancer 1999;7:79-83.
16. Kusnierczyk NMA, Saunders EF, Dupuis LL. Outcomes of antiemetic prophylaxis in children undergoing bone marrow transplantation. Bone Marrow Transplant 2002;30:119-24.
17. Braken JB, Raemaekers JM, Koopmans PP, de Pauw BE. Control of nausea and vomiting with ondansetron in patients treated with intensive non-cisplatin chemotherapy for acute myeloid leukaemia. Eur J Cancer 1993;29A:515-8.
18. Salles G, Archimbaud E, Thomas X, Fiere D. Antiemetic activity of high-dose methylprednisolone associated with continuous-infusion metoclopramide and oral aprazolam during multiple-day chemotherapy. Cancer Chemother Pharmacol 1991;28:77-9.
19. Walsh T, Morris AK, Holle LM, Callander N, Bradshaw P, Valley AW, et al. Granisetron vs ondansetron for prevention of nausea and vomiting in nematopoietic stem cell transplant patients: results of a prospective, double-blind, randomized trial. Bone Marrow Transplant 2004;34:963-8.
20. Prentice HG. Granisetron in the control of nausea and vomiting associated with bone marrow transplantation: a review of tis efficacy and tolerability. Support Care Cancer 2003;11:501-8.
21. Bubalo J, Seelig F, Karbowicz S, Maziarz RT. Randomized open-label trial of dolasetron for the control of nausea and vomiting associated with high-dose chemotherapy with hematopoietic stem cell transplantation. Biol Blood Marrow Transpl 2001;7:439-45.
22. Bosi A, Guidi S, Messori A, Saccardi R, Lombardini L, Vannucchi AM, et al. Ondansetron versus chlorpromazine for preventing emesis in bone marrow transplant recipients: a double-blind randomized study. J Chemother 1993; 5:191-6.
23. Gilbert CJ, Ohly KV, Rosner G, Peters W. Randomized, double-blind comparison of a prochlorperazine-based verus a metoclopramide-based antiemetic regimen in patients undergoing autologous bone marrow transplantation. Cancer 1995;76:2330-7.
24. Nahata MC, Hui LN, Koepke J. Efficacy and safety of ondansetron in pediatric patients undergoing bone marrow transplantation. Clin Ther 1996;18:466-76.
25. Antiemetic Subcommittee of the Multinational Association of Supportive Care in Cancer (MASCC). Consensus Conference on Antiemetic Therapy. Perugia, 2004.
26. de Wit R, Schmitz PI, Verweij J, de Boer-Dennert M, de Mulder PH, Planting AS, et al. Analysis of cumulative probabilities shows that the efficacy of 5HT3 antagonist prophylaxis is not maintained. J Clin Oncol 1996; 14:644-51.
27. Holdsworth MT, Raisch DW, Duncan MH, Chavez CM, Leasure MM. Assessment of chemotherapy-induced emesis and evaluation of a reduced-dose intravenous ondansetron regimen in pediatric outpatients with leukemia. Ann Pharmacother 1995;29:16-21.
28. de Boer-Dennert M, de Wit R, Schmitz PI, Djontono J, v Beurden V, Stoter G, et al. Patient perceptions of the side-effects of chemotherapy: the influence of 5HT3 antagonists. Br J Cancer 1997; 76:1055-61.
29. Kalaycio M, Mendez Z, Pohlman B, Overmoyer B, Boparai N, Bolwell EJ. Continuous-infusion granisetron compared to ondansetron for the prevention of nausea and vomiting after high-dose chemotherapy. J Cancer Res Clin Oncol 1998;124:265-9.
30. Belkacemi Y, Ozsahin M, Pene F, Rio B, Sutton L, Laporte JP, et al. Total body irradiation prior to bone marrow transplantation: efficacy and safety of granisetron in the prophylaxis and control of radiation-induced emesis. Int J Radiot Oncol Biol Phys 1996; 36:77-82.
31. Climent MA, Palau J, Ruiz A, Soriano V, Aznar E, Olmos T, et al. The antiemetic efficacy of granisetron plus dexamethasone, haloperidol and loracepam in breast cancer patients treated with high-dose chemotherapy with peripheral blood stem-cell support. Support Care Cancer 1998;6:287-90.
32. Abbott B, Ippoliti C, Bruton J, Neumann J, Whaley R, Champlin R. Antiemetic efficacy of granisetron plus dexamethasone in bone marrow transplant patients receiving chemotherapy and total body irradiation. Bone Marrow Transplant 1999;23:265-9.
33. Bartlett N, Koczwara B. Control of nausea and vomiting after chemotherapy: what is the evidenced Intern Med J 2002;32:401-7.
34. Spitzer TR, Friedman CJ, Bushnell W, Frankel SR, Raschko J. Double-blind, randomized, parallel-group study on the efficacy and safety of oral granisetron and oral ondansetron in the prophylaxis of nausea and vomiting in patients receiving hyperfractionated total body irradiation. Bone Marrow Transplant 2000;26:203-10.
35. Orchard PJ, Rogosheske J, Burns L, Rydholm N, Larson H, DeFor TE, et al. A prospective randomized trial of the anti-emetic efficacy of ondansetron and granisetron during bone marrow transplantation. Biol Blood Marrow Transplant 1999;5:386-93.
36. Prentice HG, Kibbler K, Prentice AG. Towards a targeted, risk based antifungal strategy in neutropenic patients. Br J Hematol 2000;110:273-84.
37. a Edición. Eds: Carreras E. Barcelona 2004: 227-32.
38. Hesketh PJ, Grunberg SM, Gralla RI, Warr DG, Roila F, de Wit R, Chawla SP, et al. The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin - the Aprepitant Protocol 052 Study Group. J Clin Oncol, 2003; 21:4112-9.
39. Warr DG, Grunberg SM, Gralla RJ, Hesketh PJ, Roila F, de Wit R, et al. The oral NK1 antagonist aprepitant for the prevention of acute and delayed chemotherapy-induced nausea and vomiting: Pooled data from 2 randomised, double-blind, placebo controlled trials. Eur J Cancer 2005;41:1278-85.
40. Warr DG, Hesketh PJ, Gralla RJ, Muss HB, Herrstedt J, Eisenberg PD, et al. Efficacy and tolerability of Aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy. J Clin Oncol 2005;23:2822-30.
41. de Witt R, Herrstedt J, Rapoport B, Carides AD, Guoguang-Ma J, Elmer M, et al. The oral NK(1) antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analysis of two randomised, placebo-controlled phase III clinical trials. Eur J Cancer 2004;40:403-10.